Journal
ARTHRITIS RESEARCH & THERAPY
Volume 13, Issue 4, Pages -Publisher
BMC
DOI: 10.1186/ar3349
Keywords
-
Categories
Funding
- Human Genome Sciences
- National Institutes of Health [R01 AR059103]
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059103] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The pathogenesis of systemic lupus erythematosus (SLE) is complex, and the resulting disease manifestations are heterogeneous. Cytokine dysregulation is pervasive, and their protein and gene expression profiles may serve as markers of disease activity and severity. Importantly, biologic agents that target specific cytokines may represent novel therapies for SLE. Four cytokines (IL-6, TNF alpha, IFN alpha, and BLyS) are being evaluated as therapeutic targets in SLE. The present review will examine the roles of each of these cytokines in murine and human SLE, and will summarize results from clinical trials of agents that target these cytokines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available